BioCentury | Nov 13, 2019
Company News

Nov. 12 Company Quick Takes: Clinical hold for Solid Bio; plus Foamix-Menlo, Chi-Med, RegeneRx and Actelion

...Paul Bonanos, Associate Editor minocycline foam (FMX103) Elunate, fruquintinib (HMPL-013) RGX-314 Opsumit, macitentan (act-064992, actelion-1) Foamix Pharmaceuticals Ltd. Hutchison China MediTech Ltd. RegeneRx Biopharmaceuticals Inc. Johnson...
BioCentury | Jul 20, 2019
Emerging Company Profile

China Ophthalmology Focus eyes Asia market

...Benjamin Li University collaborators: Hong Kong Polytechnic University, Sun Yat-Sen University Corporate partners: Kato Pharmaceuticals, RegeneRx Biopharmaceuticals Inc....
BioCentury | Mar 29, 2019
Clinical News

Lee's moving forward with dry eye candidate

...eye syndrome and neurotrophic keratitis. Lee's Pharmaceutical Holdings Ltd. (HKSE:0950) in-licensed the eye drop from RegeneRx Biopharmaceuticals Inc....
...of thymosin beta 4 (TB4), a naturally occurring 43-amino acid peptide. Elizabeth S. Eaton, Staff Writer GBT-201, RGN-259 RegeneRx Biopharmaceuticals Inc. Lee's...
BioCentury | Feb 16, 2018
Clinical News

ReGenTree reports Phase III data for RGN-259 in dry eye syndrome

...or RGN-259 eye drops given four times daily for 28 days. ReGenTree, a JV between RegeneRx Biopharmaceuticals Inc....
...acid peptide (see BioCentury, Feb. 9, 2015 ). GtreeBNT Co. Ltd. (KOSDAQ:115450), Seongnam, South Korea RegeneRx Biopharmaceuticals Inc....
...film break-up time between RGN-259 and placebo Status: Phase III data Milestone: NA Claire Quang RGN-259 GtreeBNT Co. Ltd. RegeneRx Biopharmaceuticals Inc. Thymosin...
BioCentury | Oct 6, 2017
Finance

Coasting on catalysts

...Pharmaceuticals Inc. (NASDAQ:REGN) / Sanofi (Euronext:SAN; NYSE:SNY) Kevzara sarilumab Rheumatoid arthritis Submit reg app 4Q17 RegeneRx Biopharmaceuticals Inc....
BioCentury | Jul 8, 2017
Finance

A clinical quarter

...Tel Aviv:RDHL; NASDAQ:RDHL) Bekinda ondansetron Acute gastroenteritis and gastritis Final Ph III GUARD data 3Q17 RegeneRx Biopharmaceuticals Inc....
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

...foam (FMX101) Moderate to severe acne Ph III data 1H17 GtreeBNT Co. Ltd. (KOSDAQ:115450) / RegeneRx Biopharmaceuticals Inc....
BioCentury | Oct 10, 2016
Clinical News

GBT-201: Phase III started

...given 4 times daily for 28 days in about 500 patients. ReGenTree, a JV between RegeneRx...
...is developing RGN-259 (see BioCentury, Feb. 9, 2015). GtreeBNT Co. Ltd. (KOSDAQ:115450), Seongnam, South Korea RegeneRx Biopharmaceuticals Inc....
BioCentury | Jul 11, 2016
Financial News

RegeneRx completes private placement of common stock and warrants

RegeneRx Biopharmaceuticals Inc. (OTCBB:RGRX), Rockville, Md. Business: Ophthalmic, Dermatology, Cardiovascular Date completed: 2016-06-27 Type: Private placement of common stock and warrants Raised: $1.8 million Shares: 5.1 million Price: $0.34 Shares after offering: 106.8 million Placement...
BioCentury | Mar 21, 2016
Product Development

Korea rising

...instance, in 2015 RegeneRx Biopharmaceuticals Inc. formed a JV with G-treeBNT Co. Ltd. to develop and commercialize RegeneRx's...
...year, which was certainly sooner than we expected," said J.J. Finkelstein, president and CEO of RegeneRx...
...in Korea and trying to convince them," Nam said. G-treeBNT is hoping its JV with RegeneRx...
Items per page:
1 - 10 of 137
BioCentury | Nov 13, 2019
Company News

Nov. 12 Company Quick Takes: Clinical hold for Solid Bio; plus Foamix-Menlo, Chi-Med, RegeneRx and Actelion

...Paul Bonanos, Associate Editor minocycline foam (FMX103) Elunate, fruquintinib (HMPL-013) RGX-314 Opsumit, macitentan (act-064992, actelion-1) Foamix Pharmaceuticals Ltd. Hutchison China MediTech Ltd. RegeneRx Biopharmaceuticals Inc. Johnson...
BioCentury | Jul 20, 2019
Emerging Company Profile

China Ophthalmology Focus eyes Asia market

...Benjamin Li University collaborators: Hong Kong Polytechnic University, Sun Yat-Sen University Corporate partners: Kato Pharmaceuticals, RegeneRx Biopharmaceuticals Inc....
BioCentury | Mar 29, 2019
Clinical News

Lee's moving forward with dry eye candidate

...eye syndrome and neurotrophic keratitis. Lee's Pharmaceutical Holdings Ltd. (HKSE:0950) in-licensed the eye drop from RegeneRx Biopharmaceuticals Inc....
...of thymosin beta 4 (TB4), a naturally occurring 43-amino acid peptide. Elizabeth S. Eaton, Staff Writer GBT-201, RGN-259 RegeneRx Biopharmaceuticals Inc. Lee's...
BioCentury | Feb 16, 2018
Clinical News

ReGenTree reports Phase III data for RGN-259 in dry eye syndrome

...or RGN-259 eye drops given four times daily for 28 days. ReGenTree, a JV between RegeneRx Biopharmaceuticals Inc....
...acid peptide (see BioCentury, Feb. 9, 2015 ). GtreeBNT Co. Ltd. (KOSDAQ:115450), Seongnam, South Korea RegeneRx Biopharmaceuticals Inc....
...film break-up time between RGN-259 and placebo Status: Phase III data Milestone: NA Claire Quang RGN-259 GtreeBNT Co. Ltd. RegeneRx Biopharmaceuticals Inc. Thymosin...
BioCentury | Oct 6, 2017
Finance

Coasting on catalysts

...Pharmaceuticals Inc. (NASDAQ:REGN) / Sanofi (Euronext:SAN; NYSE:SNY) Kevzara sarilumab Rheumatoid arthritis Submit reg app 4Q17 RegeneRx Biopharmaceuticals Inc....
BioCentury | Jul 8, 2017
Finance

A clinical quarter

...Tel Aviv:RDHL; NASDAQ:RDHL) Bekinda ondansetron Acute gastroenteritis and gastritis Final Ph III GUARD data 3Q17 RegeneRx Biopharmaceuticals Inc....
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

...foam (FMX101) Moderate to severe acne Ph III data 1H17 GtreeBNT Co. Ltd. (KOSDAQ:115450) / RegeneRx Biopharmaceuticals Inc....
BioCentury | Oct 10, 2016
Clinical News

GBT-201: Phase III started

...given 4 times daily for 28 days in about 500 patients. ReGenTree, a JV between RegeneRx...
...is developing RGN-259 (see BioCentury, Feb. 9, 2015). GtreeBNT Co. Ltd. (KOSDAQ:115450), Seongnam, South Korea RegeneRx Biopharmaceuticals Inc....
BioCentury | Jul 11, 2016
Financial News

RegeneRx completes private placement of common stock and warrants

RegeneRx Biopharmaceuticals Inc. (OTCBB:RGRX), Rockville, Md. Business: Ophthalmic, Dermatology, Cardiovascular Date completed: 2016-06-27 Type: Private placement of common stock and warrants Raised: $1.8 million Shares: 5.1 million Price: $0.34 Shares after offering: 106.8 million Placement...
BioCentury | Mar 21, 2016
Product Development

Korea rising

...instance, in 2015 RegeneRx Biopharmaceuticals Inc. formed a JV with G-treeBNT Co. Ltd. to develop and commercialize RegeneRx's...
...year, which was certainly sooner than we expected," said J.J. Finkelstein, president and CEO of RegeneRx...
...in Korea and trying to convince them," Nam said. G-treeBNT is hoping its JV with RegeneRx...
Items per page:
1 - 10 of 137